Keep Me Logged In
Andrew Weiss, head of pharma and biotech research at Vontobel, tells CNBC why Novartis' failure to win its battle for patent protection for the drug Glivec highlights the flaws in pharma companies' emerging market strategy.
Got a confidential news tip? We want to hear from you.
Sign up for free newsletters and get more CNBC delivered to your inbox
© 2019 CNBC LLC. All Rights Reserved. A Division of NBCUniversal
Data is a real-time snapshot *Data is delayed at least 15 minutes. Global Business and Financial News, Stock Quotes, and Market Data and Analysis.
Data also provided by